Longitude Capital Partners III, LLC

Track

Insider profile

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return 2% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Longitude Capital Partners III, LLC's trades of Inozyme Pharma Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
192.57
Quantity 91,814 -44.0%
Value US$2,438,865
Transaction date
Purchase
Price
262.93
Quantity 13,384 -32.2%
Value US$356,062
Transaction date
Purchase
Price
439.53
Quantity 72,980 +26.0%
Value US$2,648,240
Transaction date
Purchase
Price
16.00
Quantity 625,000 +28.5%
Value US$10,000,000
US 89Bio Inc (ETNB)
Transaction date
Purchase
Price
27.50
Quantity 109,090 +4.4%
Value US$2,999,975
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-04-21 2022-04-19
B Purchase
91,814 -44.0%
192.57
US$2,438,865 		91,814 -44.0% 192.57 US$2,438,865
2022-02-02 2022-02-02
B Purchase
13,384 -32.2%
262.93
US$356,062 		13,384 -32.2% 262.93 US$356,062
2021-05-11 2021-05-11
B Purchase
72,980 +26.0%
439.53
US$2,648,240 		72,980 +26.0% 439.53 US$2,648,240
2020-09-01 2020-08-28
S Sale
1,049 -100.0%
10.75
US$11,273 		1,049 -100.0% 10.75 US$11,273
2020-09-01 2020-08-28
S Sale
2,447 -100.0%
10.75
US$26,296 		2,447 -100.0% 10.75 US$26,296
2020-07-28 2020-07-28
B Purchase
625,000 +28.5%
16.00
US$10,000,000 		625,000 +28.5% 16.00 US$10,000,000
2020-07-14 2020-07-10
US 89Bio Inc (ETNB)
B Purchase
109,090 +4.4%
27.50
US$2,999,975 		109,090 +4.4% 27.50 US$2,999,975
2019-11-27 2019-11-25
B Purchase
937,000 +28.7%
8.00
US$7,496,000 		937,000 +28.7% 8.00 US$7,496,000